Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic NTRK gene fusion cancers - Supplementary materials
figure
posted on 2022-08-22, 08:56 authored by Kangho Suh, Josh J Carlson, Fang Xia, Todd Williamson, Sean D Sullivan
eFigure 1. One-way sensitivity analysis for larotrectinib vs. entrectinib on QALYs gained in colorectal cancer
eFigure 2. One-way sensitivity analysis for larotrectinib vs. entrectinib on QALYs gained in soft tissue sarcoma
eTable 1. Sensitivity analysis fitting an exponential curve through the median points for progression-free and overall survival for entrectinib
